Sökning: id:"swepub:oai:DiVA.org:kth-205249" >
Altered immunoregul...
Altered immunoregulatory profile during anti-tumour necrosis factor treatment of patients with inflammatory bowel disease
-
- Grundstroem, J. (författare)
- Karolinska Institutet
-
- Linton, L. (författare)
- Karolinska Institutet, Sweden
-
- Thunberg, Sarah, 1976- (författare)
- Karolinska Institutet
-
visa fler...
-
- Forsslund, H. (författare)
- Karolinska Institutet, Sweden
-
- Janczewska, I. (författare)
- Karolinska Institutet
-
- Befrits, R. (författare)
- Karolinska university Hospital, Sweden
-
- van Hage, M. (författare)
- Karolinska Institutet
-
- Gafvelin, G. (författare)
- Karolinska Institutet
-
- Eberhardson, M. (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2012-07-06
- 2012
- Engelska.
-
Ingår i: Clinical and Experimental Immunology. - : Oxford University Press (OUP). - 0009-9104 .- 1365-2249. ; 169:2, s. 137-147
- Relaterad länk:
-
https://www.ncbi.nlm...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Inflammatory bowel disease (IBD) can be treated effectively by anti-tumour necrosis factor (TNF) therapy. We set out to investigate the unclear immunoregulatory mechanisms of the treatment. Thirty-four patients with IBD treated with anti-TNF were included. Lymphocytes from peripheral blood and intestinal biopsies were analysed by flow cytometry. Regulation of antigen-stimulated proliferation was analysed by blocking of interleukin (IL)-10, transforming growth factor (TGF)-beta or depletion of CD25+ cells in peripheral blood mononuclear cell cultures. No changes in CD4+CD25+, CD25+TNF-RII+ or CD4+CD25+forkhead box protein 3 (FoxP3+) T cells could be observed in peripheral blood after, in comparison to before, 6 weeks of treatment. The suppressive ability of CD4+CD25+ cells did not change. There was an initial decrease of CD4+CD25+ cells in intestinal mucosa after 2 weeks of treatment, followed by an increase of these cells from weeks 2 to 6 of treatment (P < 0.05). This was accompanied by an increased percentage of CD69+ cells among these cells after 6 weeks of treatment compared to before treatment (P < 0.01). There was also an increase of mucosal T helper type1 cells from weeks 2 to 6 (P < 0.05). In addition, CD25+TNF-RII+ cells in the mucosa were decreased after 6 weeks of treatment compared to before treatment (P < 0.05). Before treatment, peripheral blood mononuclear cell baseline proliferation was increased when IL-10 was blocked (P < 0.01), but not after. In CD25+ cell-depleted cultures proliferation increased after treatment (P < 0.05). Our data indicate that anti-TNF treatment leads to an induction of effector T cells. Anti-TNF therapy has no significant impact on regulatory T cells in IBD, although the composition of regulatory T cell subsets may change during treatment.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Grundstroem, J.
-
Linton, L.
-
Thunberg, Sarah, ...
-
Forsslund, H.
-
Janczewska, I.
-
Befrits, R.
-
visa fler...
-
van Hage, M.
-
Gafvelin, G.
-
Eberhardson, M.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
- Artiklar i publikationen
-
Clinical and Exp ...
- Av lärosätet
-
Kungliga Tekniska Högskolan
-
Karolinska Institutet